SCHEMBL30108046

SCHEMBL30108046

Nc1nc(-c2ccco2)cc(-n2nnc3cc(OC4CCCC4)ccc32)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ADORA2A P29274 4/20 0.37
ADORA2B P29275 3/20 0.37
ADORA1 P30542 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
SMARCA2 P51531 9/20 0.35
PBRM1 Q86U86 9/20 0.35
SMARCA4 P51532 7/20 0.35
NR1I2 O75469 3/20 0.35
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30108071 0.93 KDM4E (0.39) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30108068 0.90 AXL (0.35) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30107951 0.84 PTGS1 (0.46) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30108028 0.83 KDM4E (0.43) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30108077 0.81 SLC6A2 (0.40) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30107980 0.80 ROCK1 (0.45) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30107959 0.79 KDM4E (0.44) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30107991 0.79 HSD17B10 (0.38) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30107986 0.79 HSD17B10 (0.38) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30108012 0.79 TSHR (0.58) KDM4EALDH1A1GAAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022203399-A1 ADENOSINE A2A RECEPTOR ANTAGONIST AND USE THEREOF 주식회사 스탠다임 2022-09-29 WO disclosed